Immuneering Corporation (NASDAQ:IMRX) Stock Has Consensus Target Price of $15.67 According to Brokerages

Shares of Immuneering Corporation (NASDAQ:IMRX) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $15.67.

Several analysts have issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a report on Monday, September 21st. HC Wainwright reiterated a “buy” rating on shares of Immuneering in a report on Friday, October 30th. UBS Group set a $14.00 price target on shares of Immuneering in a research report on Thursday, August 6th. Wall Street Zen lowered shares of Immuneering from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, Chardan Capital raised shares of Immuneering to a “strong-buy” rating in a report on Monday, August 3rd.

Immuneering Price Performance

IMRX stock opened at $3.68 on Tuesday. Immuneering has a 1 year low of $3.35 and a 1 year high of $8.48. The firm has a market capitalization of $238.32 million, a PE ratio of -3.57 and a beta of 0.49. The business has a 50 day simple moving average of $4.12 and a 200-day simple moving average of $4.77.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings data on Thursday, October 29th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.06). On average, equities research analysts expect that Immuneering will post -1.19 EPS for the current year.

Hedge Funds Weigh In On Immuneering

Several institutional investors and hedge funds have recently bought and sold shares of the company. Aberdeen Group plc purchased a new position in Immuneering in the third quarter worth approximately $3,214,000. PVG Asset Management Corp purchased a new stake in Immuneering in the first quarter valued at $773,000. Fisher Asset Management LLC raised its position in Immuneering by 31.3% in the third quarter. Fisher Asset Management LLC now owns 115,954 shares of the company’s stock valued at $475,000 after purchasing an additional 27,621 shares during the period. Weiss Asset Management LP acquired a new position in shares of Immuneering in the 1st quarter valued at $464,000. Finally, Corient Private Wealth LP acquired a new position in shares of Immuneering in the 2nd quarter valued at $385,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.

About Immuneering

Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company uses computational biology and drug-discovery technologies to identify therapeutic opportunities in complex biological pathways, with a particular emphasis on the RAS–RAF–MEK–ERK signaling pathway, which is frequently altered in cancer.

Immuneering’s lead product candidate, IMM-1-104, is an orally administered pan-RAF inhibitor designed to provide deep and durable suppression of the MAP kinase pathway while potentially limiting treatment resistance.